Young Rpe65-deficient dogs have been used as a model for human RPE65 Leber congenital amaurosis (RPE65-LCA) in proof-of-concept trials of recombinant adeno-associated virus (rAAV) gene therapy. However, there are relatively few reports of the outcome of rAAV gene therapy in Rpe65-deficient dogs older than 2 years of age. The purpose of this study was to investigate the success of this therapy in older Rpe65-deficient dogs. Thirteen eyes were treated in dogs between 2 and 6 years old. An rAAV2 vector expressing the human RPE65 cDNA driven by the human RPE65 promoter was delivered by subretinal injection. Twelve of the 13 eyes had improved retinal function as assessed by electroretinography, and all showed improvement in vision at low lighting intensities. Histologic examination of five of the eyes was performed but found no correlation between electroretinogram (ERG) rescue and numbers of remaining photoreceptors. We conclude that functional rescue is still possible in older dogs and that the use of older Rpe65-deficient dogs, rather than young Rpe65-deficient dogs that have very little loss of photoreceptors, more accurately models the situation when treating human RPE65-LCA patients.
Get full access to this article
View all access options for this article.
References
1.
AclandG.M., AguirreG.D., RayJ.et al.2001. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet., 28:92–95.
2.
AclandG.M., AguirreG.D., BennettJ.et al.2005. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol. Ther., 12:1072–1082.
3.
AguirreG.D., BaldwinV., Pearce-KellingS.et al.1998. Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. Mol. Vis., 4:23.
4.
AguirreG.K., KomaromyA.M., CideciyanA.V.et al.2007. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med., 4:e230.
5.
AnnearM.J., BartoeJ., MowatF.et al.2011a. Bright-light vision is maintained in older RPE65-deficient Dogs despite progressive decrease in photoreceptor number and reduction in residual electroretinographic function. Invest. Ophthalmol. Vis. Sci, 52, ARVO E-Abstract 1373.
6.
AnnearM.J., BartoeJ.T., BarkerS.E.et al.2011b. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther, 18:53–61.
7.
AnnearM.J., GornikK.R., VenturiF.L.et al.2012. Reproducibility of an objective four-choice canine vision testing technique that assesses vision at differing light intensities. Vet Ophthalmol., 16:324–328.
8.
BainbridgeJ.W., SmithA.J., BarkerS.S.et al.2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358:2231–2239.
9.
BaninE., Bandah-RozenfeldD., ObolenskyA.et al.2010. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum. Gene Ther., 21:1749–1757.
10.
BeltranW.A., BoyeS.L., BoyeS.E.et al.2010. rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Ther., 17:1162–1174.
11.
BennicelliJ., WrightJ.F., KomaromyA.et al.2008. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther., 16:458–465.
12.
CideciyanA.V., AlemanT.S., BoyeS.L.et al.2008. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U.S.A., 105:15112–15117.
13.
CideciyanA.V., HauswirthW.W., AlemanT.S.et al.2009. Human RPE65 gene therapy for Leber congenital amaurosis: Persistence of early visual improvements and safety at 1 year. Hum. Gene Ther., 20:999–1004.
14.
CideciyanA.V., JacobsonS.G., BeltranW.A.et al.2013. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl. Acad. Sci. U.S.A., 110:E517–E525.
15.
DejnekaN.S., SuraceE.M., AlemanT.S.et al.2004. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol. Ther., 9:182–188.
16.
Den HollanderA.I., RoepmanR., KoenekoopR.K., CremersF.P.2008. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog. Retin Eye. Res., 27:391–419.
17.
GearhartP.M., GearhartC.C., Petersen-JonesS.M.2008. A novel method for objective vision testing in canine models of inherited retinal disease. Invest. Ophthalmol. Vis. Sci., 49:3568–3576.
18.
HauswirthW.W., AlemanT.S., KaushalS.et al.2008. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther., 19:979–990.
19.
HernandezM., Pearce-KellingS.E., RodriguezF.D.et al.2010. Altered expression of retinal molecular markers in the canine RPE65 model of Leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci., 51:6793–6802.
20.
JacobsonS.G., CideciyanA.V., RatnakaramR.et al.2012. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol., 130:9–24.
21.
KijasJ.W., CideciyanA.V., AlemanT.S.et al.2002. Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. U.S.A, 99:6328–6333.
22.
Le MeurG., StiegerK., SmithA.J.et al.2007. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther., 14:292–303.
23.
LiA., ZhuX., BrownB., CraftC.M.2003. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest. Ophthalmol. Vis. Sci., 44:996–1007.
24.
LiX., LiW., DaiX.et al.2011. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci., 52:7–15.
25.
MaguireA.M., SimonelliF., PierceE.A.et al.2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358:2240–2248.
26.
MandalN., LewisG.P., FisherS.K.et al.2011. Protein changes in the retina following experimental retinal detachment in rabbits. Mol. Vis., 17:2634–2648.
27.
MarlhensF., BareilC., GriffoinJ.M.et al.1997. Mutations in RPE65 cause Leber's congenital amaurosis. Nat. Genet., 17:139–141.
28.
MowatF.M., Petersen-JonesS.M., WilliamsonH.et al.2008. Topographical characterization of cone photoreceptors and the area centralis of the canine retina. Mol. Vis., 14:2518–2527.
29.
MowatF.M., BreuwerA.R., BartoeJ.T.et al.2013. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther., 20:545–555.
30.
NakazawaT., MatsubaraA., NodaK.et al.2006. Characterization of cytokine responses to retinal detachment in rats. Mol. Vis., 12:867–878.
31.
NarfströmK., WrigstadA., NilssonS.E.1989. The Briard dog: a new animal model of congenital stationary night blindness. Br. J. Ophthalmol., 73:750–756.
32.
NarfströmK., KatzM.L., BragadottirR.et al.2003. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest. Ophthalmol. Vis. Sci., 44:1663–1672.
33.
NilssonS.E., WrigstadA., NarfstromK.1992. Changes in the DC electroretinogram in Briard dogs with hereditary congenital night blindness and partial day blindness. Exp. Eye Res., 54:291–296.
34.
PangJ.J., ChangB., HawesN.L.et al.2005. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA)Mol. Vis., 11:152–162.
35.
PangJ.J., ChangB., KumarA.et al.2006. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol. Ther., 13:565–572.
36.
Petersen-JonesS.M., BartoeJ.T., FischerA.J.et al.2009. AAV retinal transduction in a large animal model species: comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector. Mol. Vis., 15:1835–1842.
37.
RedmondT.M., YuS., LeeE.et al.1998. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat. Genet., 20:344–351.
38.
RollingF., Le MeurG., StiegerK.et al.2006. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Bull Mem. Acad. R. Med. Belg, 161:497–508, discussion 508–509.
39.
RomanA.J., BoyeS.L., AlemanT.S.et al.2007. Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis. Mol. Vis., 13:1701–1710.
40.
SamardzijaM., Von LintigJ., TanimotoN.et al.2008. R91W mutation in Rpe65 leads to milder early-onset retinal dystrophy due to the generation of low levels of 11-cis-retinal. Hum. Mol. Genet., 17:281–292.
41.
StoneE.M.2007. Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am. J. Ophthalmol., 144:791–811.
42.
VeskeA., NilssonS.E., NarfstromK., GalA.1999. Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics, 57:57–61.
43.
WrigstadA., NilssonS.E., NarfstromK.1992. Ultrastructural changes of the retina and the retinal pigment epithelium in Briard dogs with hereditary congenital night blindness and partial day blindness. Exp. Eye Res., 55:805–818.
44.
WrigstadA., NarfstromK., NilssonS.E.1994. Slowly progressive changes of the retina and retinal pigment epithelium in Briard dogs with hereditary retinal dystrophy. A morphological study. Doc. Ophthalmol., 87:337–354.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
